TCM
ALXN

Tandem Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Tandem Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,983
Closed -$1.19M – 77
2019
Q4 		$1.19M Buy
+10,983
New +$1.17M 1.02% 40

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Tandem Capital Management's ALXN Position: Q1 2020 in Review

Tandem Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 10,983 shares — an estimated $1.19M sold.

Tandem Capital Management first reported a position in ALXN in Q4 2019 and held it in 1 quarter. The position peaked at $1.19M in Q4 2019. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Tandem Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Tandem Capital Management sold 10,983 Alexion Pharmaceuticals shares in Q1 2020, an estimated $1.19M.
  • Tandem Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Tandem Capital Management's Alexion Pharmaceuticals position peaked at $1.19M in Q4 2019.
  • 653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Tandem Capital Management's 13F filing for Q1 2020, filed 12 May 2020.